Grâce à un programme de remboursement organisé en collaboration avec le Kankerfonds du Limbourg, InnoSer a récemment fait l’acquisition de deux nouveaux appareils d’imagerie qui permettront d’approfondir les connaissances sur nos plateformes in vitro et in vivo destinées à la recherche préclinique en oncologie. Le premier est l’l’ImageXpress Micro 4, unesolution d’imagerie de cellules vivantes à haut contenu, et le second est le système d’imagerie in vivo Lumina III, qui permet l’imagerie bioluminescente (BLI) de modèles in vivo.
ImageXpress Micro 4 –
Lumina III In Vivo Imaging System –
Envie d'en savoir plus ?
OECD GLP Toxicology Studies for Chemical Testing: How InnoSer Supports Your Study from Study Protocol to Report
Explore InnoSer’s GLP OECD toxicology study capabilities, from study planning and dose selection to GLP execution for chemical safety programmes.Bringing your chemical substance to the market requires a robust understanding of its potential hazards to human health and...
How do you build the right immunotoxicity assessment strategy for your nonclinical safety GLP program?
From standard toxicity studies and follow-up immune-function testing to immunogenicity assessment, test-system selection, and GLP execution, this article explores how to build an effective immunotoxicity assessment strategy for biotechnology-derived therapeutics.The...
Neurodevelopmental disorder mouse models at InnoSer — TSC, Rett & STXBP1
in this month's update, we invite you to explore recent developments in rare neurodevelopmental disorders associated with epilepsy and seizure phenotypes. We highlight emerging therapeutic approaches, discuss the importance of selecting translationally relevant...




